Perioperative immune prediction and intervention of tumor patients undergoing surgery during the novel coronavirus pneumonia (COVID-19) outbreak period

Not Applicable

Recruiting

• Conditions: cancer

• Registration Number: ITMCTR2000003138
• Lead Sponsor: Hu'nan Cancer Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

(1) aged 18-60 years;
(2) BMI in the normal range (1+/-20%);
(3) diagnosis of lung cancer, breast cancer, cervical cancer, colorectal cancer, with surgical indications, no distant metastasis;
(4) ASA grade I-II;
(5) no thymosin A1, Chinese Medicine (Bazhen Tang) use contraindications;
(6) before the test, the patients or their legal representatives understand and voluntarily sign the ethics Informed consent approved by the Committee.

Exclusion Criteria

(1) had participated in other clinical trials within 4 weeks before the start of this study;
(2) used albumin and immunoenhancer drugs within 15 days before operation;
(3) had a history of coronavirus infection, direct or indirect exposure, had fever, cough;
(4) had previous immune deficiency;
(5) had congenital metabolic abnormalities and other diseases;
(6) Patients with autoimmune diseases and infections;
(7) pregnant and lactating women;
(8) who were not willing to participate in the study for any reason.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
postoperative complication;2-year tumor-free survival and overall survival;occupancy rate of intensive care unit;

Secondary Outcome Measures

Name	Time	Method
the ratio of CD4/CD8;Treg cell;CD44+T cell;immune-inflammationindex;TNF-alpha;CD4+T cell;prognostic nutritional index;IL-17;CD8+T cell;